A clinical-stage biotechnology company commercializing a novel vaccination platform announced a potential solution for millions afraid of needles.
This vaccine innovation is essential as researchers estimate that fear of needles affects up to 25% of adults and may lead to many people skipping standard vaccinations.
Vaxxas confirmed today it initiated a Phase I clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using the Company's proprietary high-density microarray patch (HD-MAP) technology.
Read More
